Altuvoct (efanesoctocog alfa) was approved in the U.K. as a treatment for patients with moderate or severe hemophilia A ages ...

The importance of body fluids for coagulation was first described in the 1930s. At that time, the average life expectancy of hemophilia patients was just eight years.

Hemophilia B is a genetic condition that limits your blood’s ability to clot. Without prompt treatment, it can become a life threatening emergency. Creating a plan can help you better manage ...

Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...

Discover top medications for 'treating Hemophilia'? This page compiles essential information on generic and brand-name drugs specifically used for Hemophilia treatment.Here, you can explore ...

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in ...

Lackey is learning to live with a severe case of hemophilia B, a rare genetic condition that keeps blood from clotting properly. That disease required him to have surgery on his right elbow ...

Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen. The content of this ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments. Results from the Phase III FRONTIER3 trial found that Novo Nordisk’s Mim8 ...

Interim findings showed, the estimated mean annualized bleeding rate for treated bleeds was 0.53, with a median ABR of 0. Topline results were announced from a phase 3 trial evaluating Mim8 in ...